As a new generation of chemotherapy for HER-2 negative breast cancer, alpelisib acts by inhibiting phosphatidylinositol 3 (PI3) kinase, thus attenuating the AKT phosphorylation and glucose uptake. The gene discussed is AKT1; the disease is breast carcinoma.